GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » 3-Year FCF Growth Rate

SinoMab BioScience (HKSE:03681) 3-Year FCF Growth Rate : 2.50% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience 3-Year FCF Growth Rate?

SinoMab BioScience's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.12.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -29.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of SinoMab BioScience was 2.50% per year. The lowest was -99.70% per year. And the median was -44.40% per year.


Competitive Comparison of SinoMab BioScience's 3-Year FCF Growth Rate

For the Biotechnology subindustry, SinoMab BioScience's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's 3-Year FCF Growth Rate falls into.



SinoMab BioScience 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


SinoMab BioScience  (HKSE:03681) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


SinoMab BioScience 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience (HKSE:03681) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Liu Wenyi 2201 Interest of corporation controlled by you
Leung Shui On 2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines